Figure 1
The endocrine role of bone: osteocalcin and beyond. Arrows: continuous, accepted; dashed, speculative; black, known interactions;
green, indirect interactions; red, direct interactions; blue, osteokines. A feed-forward loop links insulin, bone resorption
and osteocalcin activity. Insulin signalling in osteoblasts decreases the expression of Opg by decreasing the ratio of Opg (a RANKL decoy receptor) to RANKL, thus increasing bone resorption by osteoclasts. This osteoclastic bone resorption generates
an acidic pH in the resorption lacunae necessary to decarboxylate osteocalcin stored in the bone extracellular matrix. Undercarboxylated
osteocalcin (GLU13-OC) is released into the bloodstream, affecting glucose metabolism by binding to the osteocalcin receptor
(GPRC6A), thus stimulating insulin secretion and β-cell proliferation in the pancreas and promoting insulin sensitivity in
peripheral organs. In addition, GLU13-OC promotes male fertility by stimulating testosterone synthesis in Leydig cells of
the testis through GPRC6A activation. OST-PTP acts as an inhibitor, dephosphorylating the IR and suppressing the levels of
GLU13-OC. To complete this feed-forward loop, peripheral/central tissues (adrenal gland, adipose tissue and pancreas) can
further indirectly regulate the release of GLU13-OCN into the peripheral circulation. New emerging evidence indicates that,
in addition, NPP1 can indirectly inhibit GLU13-OCN release via OPG. Independently of OCN, osteoblast-specific proteins (PHOSPHO1,
AMPK and GSK3β) can influence insulin secretion from β-cells, their functions and adiposity. Osteocyte-derived factors – osteokines
– may also be implicated in the endocrine regulation of glucose metabolism (figure adapted from Rosen & Motyl (2010) and Ferron
& Lacombe (2014)).